Children with cancer need not just treatment, but systems that help families recognize symptoms early.
In Chicago this May, Ghanaian pediatric oncologist Dr. Emmanuella Amoako received the 2026 Pediatric Oncology Yvonne Award — a recognition that speaks not only to one physician's accomplishments but to the deeper question of whose children are counted in the global story of cancer care. Working from Cape Coast Teaching Hospital and across multiple research initiatives, Amoako has spent her career dismantling the structural barriers — geographic, diagnostic, genomic, and ethical — that have long rendered African children with cancer unseen by the systems meant to save them. Her work is a reminder that equity in medicine is not a destination but a practice, built one shared-care model, one community navigator, one biobank at a time.
- Children with cancer in Africa face a compounding crisis: delayed diagnosis, treatment abandonment, and near-total exclusion from the clinical trials that define global standards of care.
- At Cape Coast Teaching Hospital, Dr. Amoako pioneered a shared-care model that keeps families rooted in their communities while receiving specialized oncology treatment — directly attacking the abandonment rates that quietly devastate survival statistics.
- Through the PROGRESS study, she is building the molecular diagnostics and biobanking infrastructure that Africa has largely lacked, pushing back against a research landscape where African cancer biology remains underrepresented and understudied.
- The COMPASS initiative trains parents as community navigators armed with a digital referral app, turning families themselves into the first line of early detection in settings where fragmented systems and stigma cause fatal delays.
- With over twenty peer-reviewed publications, a Harvard bioethics degree in progress, and platforms at ASCO and St. Jude Global Alliance, Amoako is reshaping not just clinical practice but the international conversation about who leads African oncology research.
When Dr. Emmanuella Amoako accepted the Pediatric Oncology Yvonne Award at OncoDaily Party 2026 in Chicago, the honor recognized something larger than a career — it acknowledged a sustained effort to ensure that children with cancer in Africa receive the same precision, access, and research investment as children anywhere else.
At Cape Coast Teaching Hospital, where she leads the Pediatric Oncology Unit serving Ghana's Central and Western regions, Amoako built a shared-care model that connects hospital specialists with local providers, allowing families to remain in their communities during treatment. In settings where the cost and disruption of long-term displacement cause many families to abandon care entirely, this structural innovation is not a convenience — it is a survival strategy.
Her research work runs equally deep. As Director of Clinical Affairs at Yemaachi Biotech since 2021, she co-leads PROGRESS, a multi-site study using next-generation sequencing to detect minimal residual disease in pediatric leukemia while establishing biobanking infrastructure and a longitudinal cancer cohort — resources that have been conspicuously absent from African oncology. She also contributed to the AMBER Study, the first African-led liquid biopsy study in metastatic breast cancer. A paper she published in BMJ Global Health — titled 'Unseen and unheard: African children with cancer are consistently excluded from clinical trials' — names plainly what her research addresses structurally.
Before treatment can begin, diagnosis must happen. As Principal Investigator of the COMPASS initiative, funded by MSD and Foundation S, Amoako trains parent navigators to recognize early cancer warning signs in their communities and guide families toward care through a digital referral app. It is a model born of practical necessity: symptoms are misread, referral systems are fragmented, and families face geographic and financial walls that delay care until it is too late.
Amoako's formation spans Luhansk State Medical University, the Ghana College of Physicians, and a Harvard Medical School MSc in Bioethics — a combination that positions her simultaneously as clinician, researcher, ethicist, and systems architect. She is inaugural secretary of the Childhood Cancer Society of Ghana, lead pediatrician for Operation Smile Ghana, co-founder of the Global Health Unfiltered podcast, and author of four children's books on cancer designed to give families language and reduce stigma. The Yvonne Award joins an ASCO IDEA Award, a SIOP Global Health honor, and other recognitions — but its deepest significance lies in what it reflects: the slow, deliberate construction of an ecosystem in which pediatric oncology in Ghana can generate its own evidence, train its own leaders, and speak for its own children.
On a May evening in Chicago, Emmanuella Amoako stood to receive the Pediatric Oncology Yvonne Award, recognition that carried weight far beyond the ceremony itself. The honor, presented at OncoDaily Party 2026, acknowledged not just a career but a vision: that children with cancer in Africa deserve the same precision, access, and research attention as children anywhere else in the world.
Amoako is a pediatric hematologist-oncologist at Cape Coast Teaching Hospital in Ghana, where she leads the Pediatric Oncology Unit serving Central and Western regions. Her clinical work there centers on a deceptively simple but transformative idea—that specialized cancer care doesn't have to mean families must abandon their homes and communities. She pioneered a shared-care model designed to bring treatment closer to children and their families, maintaining connections between hospital specialists and local providers. In settings where treatment abandonment remains one of the largest barriers to survival, this structural shift matters enormously. It's not just about proximity; it's about trust, continuity, and the practical reality that families with limited resources cannot sustain long-term displacement.
But Amoako's work extends far beyond the clinic. Since 2021, she has served as Director of Clinical Affairs at Yemaachi Biotech, where she oversees research strategy and partnerships. There, she co-leads PROGRESS, the Pediatric Oncology in Ghana Research Study Sites initiative, which is pioneering next-generation sequencing for detecting minimal residual disease in pediatric acute lymphoblastic leukemia. The study also establishes multisite biobanking and a longitudinal pediatric cancer cohort—infrastructure that has been largely absent in African oncology. She contributed to the AMBER Study, described as the first African-led liquid biopsy study in metastatic breast cancer, and has co-authored research on actionable genomic alterations in Ghanaian metastatic breast cancer cases. This work addresses a fundamental inequity: children and adults with cancer in Africa have been systematically excluded from the clinical trials and genomic studies that shape global standards of care, meaning treatments developed and refined elsewhere may not reflect African cancer biology or populations.
Amoako's training reflects this systems-level thinking. She earned her medical degree from Luhansk State Medical University in Ukraine and completed fellowship training through the Ghana College of Physicians. She is pursuing an MSc in Bioethics at Harvard Medical School, a choice that signals her commitment to the ethical dimensions of global health research. She holds certifications in good clinical practice, cancer genetic risk counseling, and leadership in global health through the University of Washington. This combination—clinician, researcher, ethicist, systems thinker—positions her to work across patient care, research strategy, clinical trials, and health policy simultaneously.
One of her most direct interventions addresses a crisis that precedes treatment: delayed diagnosis. She serves as Principal Investigator of COMPASS, funded by MSD and Foundation S, which trains parents as navigators in their communities to recognize early signs of childhood cancer and guide families toward appropriate care. The project uses a digital app to improve referral pathways from communities to treatment centers. Childhood cancer symptoms are often misunderstood or attributed to other causes; families face geographic and financial barriers; referral systems are fragmented. Parent navigators become trusted community links, helping other families recognize warning signs and reach care faster. It is a model rooted in practical necessity rather than theory.
Amoako's voice in the global conversation about African oncology has grown steadily. She has published more than twenty peer-reviewed articles, including one in BMJ Global Health titled "Unseen and unheard: African children with cancer are consistently excluded from clinical trials," which names directly what her research work addresses indirectly. She has spoken at the St. Jude Global Alliance, ASCO, the Harvard T.H. Chan Africa Health Conference, and the Roche Symposium, each time centering the needs of African children and the necessity of locally led research. She is the inaugural secretary of the Childhood Cancer Society of Ghana, lead pediatrician for Operation Smile Ghana, and co-founder of the Global Health Unfiltered podcast. She has also written four children's books on cancer—a recognition that families and children themselves need education, language, and tools to understand disease and reduce stigma.
Her previous honors include the ASCO IDEA Award in 2024, the SIOP Best of Global Health Abstract in 2021, the Johnson & Johnson Global Citizen Award in 2017, and the Oxford WT Global Health Small Grant in 2022. The Yvonne Award joins these recognitions, but it carries particular significance because it honors not just individual achievement but the systems-building work that makes individual achievement sustainable. Through Cape Coast Teaching Hospital, Yemaachi Biotech, the University of Ghana Medical Centre, and multiple national and international initiatives, Amoako is constructing the infrastructure—clinical, research, diagnostic, educational, and community-based—that allows pediatric oncology in Ghana to evolve from a resource-constrained specialty into a field capable of generating its own evidence and training its own leaders.
Notable Quotes
African children with cancer are consistently excluded from clinical trials that shape global standards of care— Dr. Amoako, BMJ Global Health publication
Treatment abandonment remains a major barrier in many low- and middle-income settings; shared-care models can play an important role in improving access, trust, follow-up, and treatment completion— Recognition statement from Yvonne Award citation
The Hearth Conversation Another angle on the story
Why does it matter that African children are excluded from clinical trials? Isn't the science the same everywhere?
The science of cancer biology isn't the same everywhere. Genetic variations, environmental factors, and how diseases present can differ across populations. When trials exclude African children, we develop treatments based on other populations' biology, then apply them without knowing if they work as well or safely for African children. We're also losing the chance to understand cancer in African populations at all.
So the shared-care model at Cape Coast—that's not just about convenience?
It's about survival. Families can't afford to leave their homes for months of treatment. They abandon care. A shared-care model keeps children connected to specialists while staying rooted in their communities. It's a structural solution to a structural problem.
What does a parent navigator actually do in COMPASS?
They live in the community. They know the families. When a child has symptoms that might be cancer, the navigator helps the family recognize it, understand it's serious, and get to the right hospital. They bridge the gap between community and clinic—and that gap is often where children get lost.
Why pursue bioethics at Harvard while running a pediatric oncology unit in Ghana?
Because research ethics matter most in places with the least power. If you're doing research in low-resource settings, you need to understand not just the science but the justice questions. Who benefits? Who bears the risk? How do you build trust? That's not abstract—it shapes every study we run.
What does it mean that she's written children's books about cancer?
It means she understands that oncology isn't just clinical. Families need language, stories, ways to talk about disease without shame. A child's book can do what a medical journal can't—it reaches families before crisis, it normalizes conversation, it reduces stigma. That's systems-building too.